Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Ceftaroline Effective Against Community-Acquired Pneumonia in Hospitalised Patients: Presented at ICAAC By Charlene Laino SAN FRANCISCO --- September 21, 2009 -- Ceftaroline has the potential to be an effective, well-tolerated option for the treatment of community-acquired pneumonia in hospitalised patients, researchers said here at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Paul B. Eckberg, MD, Cerexa, Inc., Oakland, California, presented an analysis of 2 international, multicentre phase 3 studies of the drug here on September 12. “With ceftaroline, we have a next generation cephalosporin that has been shown to have additional in vitro activity against resistant gram-positive bacteria,” Dr. Eckberg said. The trials, known as FOCUS 1 and FOCUS 2, involved 1,228 hospitalised adult patients with mild to moderate community-acquired pneumonia requiring intravenous therapy. Patients were randomised in a 1:1 ratio to receive ceftaroline 600 mg every 12 hours or the standard cephalosporin ceftriaxone 1 g every 24 hours for 5 to 7 days. Baseline characteristics were comparable between the groups. The combined results of the trials demonstrated a clinical cure rate of 84.3% for patients treated with ceftaroline versus 77.7% for patients treated with ceftriaxone in the integrated clinically evaluable patient population. The overall microbiological response rate in the microbiologically evaluable population was 87% for ceftaroline-treated patients and 81% for ceftriaxone-treated patients, and in the microbiological modified intent-to-treat population it was 84.8% for the ceftaroline group and 80.4% for the ceftriaxone group. Ceftaroline was generally well tolerated, with a side-effect profile similar to ceftriaxone. The most common adverse effects for ceftaroline were diarrhoea, headache, and insomnia. Funding for this study was provided by Forest Laboratories Inc. [Presentation title: FOCUS 1 and 2: Randomized, Double-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline (CPT) vs Ceftriaxone (CRO) in Community-Acquired Pneumonia (CAP). Abstract L1-345a] E-mail this page to a friend or colleague! To print, use this version